Becton Dickinson & Co. (NYSE:BDX) said Tuesday it closed its purchase of biotech firm Cellular Research for an undisclosed price.
Cellular Research develops tools for parallel single cell genetic analysis based upon its proprietary molecular indexing technology, according to Franklin Lakes, N.J.-based Becton Dickinson.
“The acquisition of Cellular Research, combined with our existing cell sorting technology, will provide our customers with a more complete and simplified workflow solution for single cell analysis. The addition of Cellular Research builds on our GenCell acquisition and underscores BD’s commitment to a genomics strategy focused on next generation sequencing sample preparation,” BD life sciences prez Linda Tharby said in a press release.
BD has been collaborating with Cellular Research since 2014 to develop single cell analysis workflows that operated with both company’s tech platforms, BD said.
“Integrating BD’s single cell sorting capabilities and world-leading expertise with our next generation single cell genomic technologies will provide researchers with a scalable, cost-effective approach to high resolution gene expression studies. We are excited about the possibilities we can offer researchers by combining our expertise, and believe it has the potential to meet several unmet needs in single cell genomics research,” Cellular Research CEO Stephen Fodor said in prepared remarks.
The acquisition is small compared to BD’s $12.2 billion merger with CareFusion, which closed in March after European anti-trust regulators approved the deal.
Franklin Lakes, N.J.-based Becton agreed last October to pay a total of $58.00 a share – $49.00 in cash and 0.0777 of a BDX share – for each CFN share, representing a premium of 26% to the closing price on Oct. 3.
The deal unites 2 complementary product lines: BD makes products to deliver and administer drugs, such as disposable needles, syringes and intravenous catheters, while CareFusion makes products to store and deliver drugs, such as infusion pumps.
Anti-trust regulators in the U.S. approved the deal last November; the EU nod was the buyout’s final regulatory hurdle, according to a regulatory filing. In January CareFusion and BD agreed to settle a raft of lawsuits filed by shareholders seeking to block the merger. CareFusion’s shareholders OK’d the deal later that month.